Ranitidine: Difference between revisions
Ostermayer (talk | contribs) (Text replacement - "Category:Drugs" to "Category:Pharmacology") |
Neil.m.young (talk | contribs) (Text replacement - "==Sources==" to "==References==") |
||
| Line 50: | Line 50: | ||
==See Also== | ==See Also== | ||
== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Revision as of 00:35, 26 June 2016
General
- Type: H2 blocker
- Dosage Forms: 75, 150, 300
- Common Trade Names: Zantac
Adult Dosing
GERD: 150 mg PO BID
Pediatric Dosing
GERD: 5-10 mg/kg/day PO BID
Special Populations
- Pregnancy Rating: B
- Lactation: Probably Safe
- Renal Dosing
- Adult: CrCl < 50: 150 mg Qday; CrCl < 10: 75 -150 mg Qday; HD: give dose after dialysis
- Pediatric: CrCl < 10-50: decrease dose 50%; CrCl< 10: decrease dose 75%; HD: Give dose after dialysis
- Hepatic Dosing
- Adult: Not defined
- Pediatric: not defined
Contraindications
- Allergy to class/drug
- Porphyria
- Caution if impairment of liver or kidneys
- Caution in chronic pulmonary disease
- Caution if diabetes mellitus
- Caution if immunocompromised
Adverse Reactions
Serious
- Thrombocytopenia
- Hepatotoxicity
- Pneumonia
Common
- Nausea/vomiting/diarrhea
- Fatigue
- Headache
- Rash
- Myalgia
- Xerostomia
Pharmacology
- Half-life: 2-3 hr, Renal impairment: 5 hr
- Metabolism: Liver
- Excretion: Urine, Feces
- Mechanism of Action: H2 blocker
